This month's top tech news stories
Thermo Fisher Scientific
Identifying Omicron
Thermo Fisher has confirmed that its TaqPath COVID-19 Combo Kit, and TaqPath COVID-19 CE-IVD RT-PCR Kit can accurately detect the presence of the Omicron variant in SARS-CoV-2 samples.
The test uses the primer-probe detection method and is not affected by the emerging Omicron variant. The TaqPath COVID-19 assays detect SARS-CoV-2 infections by identifying the presence of three gene targets from the orf1a/b, S, and N regions of the virus.
Eagle Genomics
Microbiome data
Eagle Genomics, a pioneer in applying network science to biology, and Frost & Sullivan, the global market analyst, have announced a partnership to deliver insights on the transformative role and potential of microbiome technologies to improve health and wellness.
The first fruit of the partnership is a new research report, entitled Microbiome Technologies Transforming Health & Wellness, covering a number of case studies on a range of microbiome data-driven innovations.
Infex Therapeutics
Potential COVID Drug
An infectious disease and biotech company has announced a breakthrough in trials of a new drug to treat COVID-19, including infection with the Omicron variant.
Infex Therapeutics’ COV-X programme inhibits a new protease target that is responsible for viral replication across the broad spectrum of SARS-CoV-1, MERS-CoV and SARS-CoV-2. As such, this new approach is unaffected by changes to coronavirus spike protein.
Exciting results at Infex have identified new compounds with a balance of high potency and encouraging all-round properties, such as solubility and in-vitro metabolism.
Image credit | Thermo-Fisher-Scientific| iStock| Shutterstock